Augnition Labs
Augnition Labs develops AI-enabled digital assessment and monitoring solutions for early detection of cognitive decline. Founded in 2020 on >15 years of neuroscience research, the company builds digital cognitive tests that target pattern separation and works with academic partners and healthcare settings to validate and deploy prescription-use cognitive assessment tools.
Industries
Nr. of Employees
small (1-50)
Products
AugMem
A prescription-use digital cognitive assessment aid designed to evaluate memory-related pattern separation and detect subtle cognitive changes for clinical and research use.
AugMem
A prescription-use digital cognitive assessment aid designed to evaluate memory-related pattern separation and detect subtle cognitive changes for clinical and research use.
Services
Provision of a prescription-use cognitive assessment platform for use by healthcare professionals, clinical researchers, and academic partners, including integration into research studies and clinical workflows.
Provision of a prescription-use cognitive assessment platform for use by healthcare professionals, clinical researchers, and academic partners, including integration into research studies and clinical workflows.
Expertise Areas
- Digital cognitive assessment
- AI/ML for neurotechnology
- Digital biomarker development
- Clinical trial methodology for neurological assessments
Key Technologies
- Digital cognitive testing
- Pattern separation-targeted tasks
- AI and machine learning
- Cloud-based assessment platform
News & Updates
Company was a featured sponsor and exhibitor at the 2023 International Conference on Learning and Memory to engage with learning and memory researchers.
Press release announcing FDA classification of the company's prescription-use cognitive assessment aid to support clinical deployment.
Announcement of the company's cognitive test suite being included in a large NIH-funded research network to collect population-scale cognition and biomarker data.
Received a Small Business Innovation Research grant to develop and scale the company's cognitive assessment platform.
Regulatory milestone classifying the assessment platform as a Prescription Use Cognitive Assessment Aid (PTY) enabling clinical deployment.
Company was a featured sponsor and exhibitor at the 2023 International Conference on Learning and Memory to engage with learning and memory researchers.
Press release announcing FDA classification of the company's prescription-use cognitive assessment aid to support clinical deployment.
Announcement of the company's cognitive test suite being included in a large NIH-funded research network to collect population-scale cognition and biomarker data.
Received a Small Business Innovation Research grant to develop and scale the company's cognitive assessment platform.
Regulatory milestone classifying the assessment platform as a Prescription Use Cognitive Assessment Aid (PTY) enabling clinical deployment.